Sean Nolan serves as the Chief Executive Officer and Director at Taysha Gene Therapies, Inc., a company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. With a robust background in the biopharmaceutical industry, Nolan brings a wealth of experience and leadership to his role at Taysha. Prior to joining Taysha, he held the position of President and Chief Executive Officer at Spark Therapeutics, where he played a pivotal role in the company's growth and eventual acquisition by Roche for $4.3 billion in 2019. Under his leadership, Spark became the first company to receive FDA approval for a gene therapy product for a genetic disease, Luxturna, which treats a rare form of inherited vision loss. Nolan's career also includes significant roles at companies such as Sanofi Genzyme and Pfizer, where he honed his skills in strategic planning, business development, and operational execution. At Sanofi Genzyme, he served as Senior Vice President and Chief Business Officer, overseeing the company's business development and strategic partnerships. His tenure at Pfizer saw him in various leadership positions, including Senior Vice President of Business Development and Strategic Alliances, where he was instrumental in driving the company's growth through innovative collaborations and acquisitions. Nolan's extensive experience in the biotech sector, combined with his proven track record of leading companies through successful growth and commercialization phases, positions him well to guide Taysha Gene Therapies in its mission to bring transformative treatments to patients with severe genetic diseases. At Taysha Gene Therapies, Nolan's role as CEO and Director involves overseeing the company's strategic direction, operational activities, and the development of its gene therapy pipeline. His leadership is crucial in navigating the complex landscape of gene therapy development and regulatory approval, ensuring that Taysha remains at the forefront of innovation in the field. Under his guidance, Taysha aims to advance its portfolio of therapies, build strategic partnerships, and ultimately improve the lives of patients suffering from debilitating genetic conditions. Nolan's vision and expertise are key drivers in Taysha's pursuit of becoming a leader in the gene therapy space.